MacuLogix closes $38.7M financing round — 4 insights

Written by Eric Oliver | March 07, 2019 | Print  |

Macular degeneration solutions company MacuLogix closed a $38.7 million financing round, Invision reports.

What you should know:

1. MacuLogix provides instruments, tools and education to treat age-related macular degeneration patients.

2. Vivo Capital led the series D round, with contributions from four other firms.

3. MacuLogix raised a $51 million in venture funding and $10 million in venture debt.

4. "With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company's vision to eliminate blindness caused by AMD," said MacuLogix CEO and President William D. McPhee.

More articles on leadership:
How total joints propelled an Ohio-based ASC's strategy for growth and a bigger location
Fox Valley Orthopedics' Dr. Vishal Mehta on total joint replacement
Orthopedic trauma, spine & more: 3 trends, growth areas for ASCs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.